KBC Group NV Sells 432,494 Shares of Kenvue Inc. (NYSE:KVUE)

KBC Group NV decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 44.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 533,666 shares of the company's stock after selling 432,494 shares during the quarter. KBC Group NV's holdings in Kenvue were worth $11,394,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Grove Bank & Trust increased its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the 4th quarter valued at about $29,000. Riverview Trust Co acquired a new stake in Kenvue in the 3rd quarter valued at about $30,000. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $35,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on KVUE. JPMorgan Chase & Co. raised their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Piper Sandler upgraded shares of Kenvue from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $26.00 in a report on Monday, January 6th. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research note on Monday, December 9th. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $23.08.

Kenvue Price Performance

Kenvue stock traded up $0.42 during midday trading on Thursday, hitting $21.73. The company's stock had a trading volume of 4,806,289 shares, compared to its average volume of 11,132,580. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock's 50-day moving average price is $22.00 and its 200-day moving average price is $21.85. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market capitalization of $41.65 billion, a PE ratio of 39.50, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the previous year, the business posted $0.31 EPS. The business's revenue for the quarter was down .4% on a year-over-year basis. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.77%. Kenvue's dividend payout ratio (DPR) is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.